Patients with Parkinson’s disease (PD) who are taking levodopa therapy – the most widely-used agent to treat the illness – may experience the effects of their medication “wearing off” sooner than their health care providers realize. New data presented Oct. 19 at the Parkinson’s Study Group meeting in San Francisco concluded that a specifically-designed patient questionnaire identified symptoms related to “wearing off” more frequently than a clinical assessment by a movement disorder specialist.
“Although levodopa remains the foundation of Parkinson’s disease therapy, the medical community has long recognized that its use can be limited due to the inability to control Parkinson’s disease symptoms over time,” said investigator Robert A. Hauser, M.D., M.B.A., director of the Parkinson’s Disease and Movement Disorders Center of the University of South Florida in Tampa and member of an international consortium of researchers known as the End-of-Dose Wearing Off (EODWO) Working Group. “However, this study shows that end-of-dose ‘wearing off’ may be a bigger problem for Parkinson’s disease patients than physicians and other members of the health care community realize.”
Within one to two years, almost 50 percent of PD patients receiving levodopa therapy begin to notice that their medication lasts for shorter periods, causing symptoms to re-emerge before the next dose. This phenomenon is known as “wearing off.” Eventually, the effect of a levodopa dose may decrease from eight hours when patients begin levodopa therapy to only one to two hours. “Wearing off” is associated with the re-emergence of motor symptoms (e.g. tremor and problems with balance), non-motor symptoms (e.g. anxiety, fatigue, mood changes, and restlessness), and autonomic nervous system dysfunction (e.g. sweating and hypersalivation).
Marissa Emerson | University of South Florida
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine